What is the optimal management for a parasagittal/falcine meningioma abutting the superior sagittal sinus with adjacent skull hyperostosis?

Parasagittal/Falcine Meningioma with Superior Sagittal Sinus Involvement and Skull Hyperostosis

Clinical Characteristics and Presentation

Parasagittal and falcine meningiomas with superior sagittal sinus (SSS) involvement and hyperostosis represent surgically challenging lesions that present with more severe clinical manifestations and require careful treatment planning. These tumors demonstrate distinct features that influence management decisions 1.

Key Clinical Features:

• More aggressive presentation: Higher rates of emergency department admissions and seizure presentation compared to non-hyperostotic meningiomas 1
• Radiographic characteristics:
  • Increased perilesional edema
  • Midline shift
  • Non-homogeneous enhancement
  • T2 hyperintense signal
  • High association with bone invasion 1
• Location specificity: Hyperostotic meningiomas preferentially occur in certain locations, particularly olfactory groove 1

Hyperostosis Pathophysiology:

The hyperostosis is driven by secreted pro-osteogenic factors (BMP3, RBP4, MATN4, CILP2, FGF7) rather than simple reactive bone changes, with 55% of upregulated genes being secreted proteins related to skeletal development 1. Importantly, hyperostosis correlates with lower Ki-67 proliferative indices and is associated with bone invasion and skull base location 2.

Treatment Algorithm

Primary Treatment Decision Framework:

For symptomatic or growing tumors, the optimal approach prioritizes maximal safe resection while preserving venous structures, followed by adjuvant stereotactic radiosurgery (SRS) for residual disease rather than aggressive sinus reconstruction 3, 4, 5.

1. Surgical Strategy (When Indicated)

The venous-sparing approach is recommended to minimize morbidity while achieving tumor control 4, 5:

• Do NOT cross the SSS during craniotomy 4
• Do NOT resect the falx unless SSS is already occluded 4, 5
• Preserve all functional bridging cortical veins 5
• Use motor evoked potentials (MEPs) intraoperatively to avoid eloquent cortex damage 4
• Consider selective preoperative embolization 4

Specific surgical decision points based on SSS status:

• If SSS is patent: Perform maximal tumor resection without entering the sinus, leaving intra-sinus tumor remnant 5, 6
• If SSS is already occluded by tumor: Resect the occluded portion of sinus and adjacent falx 5

Expected surgical outcomes with this approach:

• Gross total resection (GTR): 51.7% 4
• Near-GTR: 48.3% 4
• New permanent neurological deficit: 1-5.2% 4, 5
• Overall complication rate: 8.6-13% 4, 6
• Mortality: 0% 6

Critical surgical considerations for hyperostotic tumors:

• Increased intraoperative blood loss 1
• Longer operative times 1
• Mandatory cranioplasty planning due to hyperostotic bone removal 7, 1
• Consider custom-made cranioplasty with frame-based craniectomy 7

2. Stereotactic Radiosurgery (Primary or Adjuvant)

SRS is an effective evidence-based treatment option (Level II recommendation) for WHO grade I meningiomas 3:

Indications for SRS:

• Primary treatment for asymptomatic, incidental lesions under observation that demonstrate growth 8
• Adjuvant treatment for residual intra-sinus tumor after subtotal resection 9, 6
• Salvage treatment for recurrent tumor growth 9

SRS dosing and outcomes:

• Prescription dose: 12-15 Gy single fraction 3
• 10-year local control: 71-100% 3
• 10-year progression-free survival: 55-97% 3
• Toxicity: Generally low 3
• Perilesional edema: Key toxicity signal to monitor 8

Specific outcomes for SSS-involving meningiomas treated with RRS:

• 5-year recurrence probability: 0% (primary treatment), 8.3% (adjuvant), 21.5% (recurrent) 9
• No acute sinus venous thrombosis or venous congestion-associated bleeding occurred with radiosurgery 9

3. Observation Strategy

For incidental, asymptomatic suspected meningiomas, observation with serial imaging is appropriate 8. This aligns with the 2021 European Association of Neuro-Oncology guideline recommendation 8.

Critical finding: Subtotal resection of WHO Grade I tumor followed by close observation shows no difference in tumor control compared to GTR, primarily because intra-sinus tumor remnants rarely demonstrate interval growth on serial imaging 6.

Management Algorithm Summary

Step 1: Determine symptom status and growth pattern

• Asymptomatic, stable → Observation
• Symptomatic or growing → Proceed to Step 2

Step 2: Assess SSS patency and surgical risk

• Patent SSS with high surgical risk → Primary SRS
• Patent SSS with acceptable risk → Venous-sparing surgery + adjuvant SRS for residual
• Occluded SSS → Resection including occluded sinus segment

Step 3: Plan for hyperostosis management

• Preoperative custom cranioplasty planning mandatory
• Anticipate increased operative time and blood loss
• Ensure adequate bone removal including hyperostotic margins

Step 4: Adjuvant therapy decision

• Residual intra-sinus tumor after subtotal resection → Observe initially, SRS only if growth documented
• Immediate adjuvant SRS can be considered for higher-grade features

Critical Pitfalls to Avoid

1. Do NOT pursue aggressive SSS reconstruction in pursuit of Simpson Grade I resection—this increases morbidity without improving tumor control when combined with modern adjuvant therapies 5, 6

2. Do NOT sacrifice functional bridging veins—venous infarction risk outweighs benefit of more complete resection 4, 5

3. Do NOT underestimate hyperostosis impact—these tumors require longer operative times, cranioplasty planning, and have higher intraoperative blood loss 1

4. Do NOT immediately treat all residual intra-sinus tumor—observation is appropriate as these remnants rarely grow, and SRS can be reserved for documented progression 6

5. Hyperostosis does NOT correlate with WHO grade or aggressive histology—it actually correlates with lower Ki-67 indices 2